197 related articles for article (PubMed ID: 17024505)
1. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit.
Yakovlev SV; Stratchounski LS; Woods GL; Adeyi B; McCarroll KA; Ginanni JA; Friedland IR; Wood CA; DiNubile MJ
Eur J Clin Microbiol Infect Dis; 2006 Oct; 25(10):633-41. PubMed ID: 17024505
[TBL] [Abstract][Full Text] [Related]
2. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.
Paladino JA; Eubanks DA; Adelman MH; Schentag JJ
J Am Geriatr Soc; 2007 May; 55(5):651-7. PubMed ID: 17493183
[TBL] [Abstract][Full Text] [Related]
3. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Vetter N; Cambronero-Hernandez E; Rohlf J; Simon S; Carides A; Oliveria T; Isaacs R;
Clin Ther; 2002 Nov; 24(11):1770-85. PubMed ID: 12501873
[TBL] [Abstract][Full Text] [Related]
5. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
[TBL] [Abstract][Full Text] [Related]
6. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
[TBL] [Abstract][Full Text] [Related]
7. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
Wells WG; Woods GL; Jiang Q; Gesser RM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem.
Holsen MR; Wardlow LC; Bazan JA; Fussner LA; Coe KE; Elefritz JL
Int J Antimicrob Agents; 2019 Dec; 54(6):824-828. PubMed ID: 31319191
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
[TBL] [Abstract][Full Text] [Related]
10. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Namias N; Solomkin JS; Jensen EH; Tomassini JE; Abramson MA
Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
[TBL] [Abstract][Full Text] [Related]
11. A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections.
Badaró R; Molinar F; Seas C; Stamboulian D; Mendonça J; Massud J; Nascimento LO;
Braz J Infect Dis; 2002 Oct; 6(5):206-18. PubMed ID: 12495602
[TBL] [Abstract][Full Text] [Related]
12. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae.
Blanchette LM; Kuti JL; Nicolau DP; Nailor MD
Scand J Infect Dis; 2014 Nov; 46(11):803-8. PubMed ID: 25262922
[TBL] [Abstract][Full Text] [Related]
13. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
14. Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone.
Legua P; Lema J; Moll J; Jiang Q; Woods G; Friedland I
Clin Ther; 2002 Mar; 24(3):434-44. PubMed ID: 11952026
[TBL] [Abstract][Full Text] [Related]
15. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
16. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
Merz LR; Warren DK; Kollef MH; Fridkin SK; Fraser VJ
Chest; 2006 Dec; 130(6):1672-8. PubMed ID: 17166981
[TBL] [Abstract][Full Text] [Related]
17. Prospective monitoring of cefepime in intensive care unit adult patients.
Chapuis TM; Giannoni E; Majcherczyk PA; Chioléro R; Schaller MD; Berger MM; Bolay S; Décosterd LA; Bugnon D; Moreillon P
Crit Care; 2010; 14(2):R51. PubMed ID: 20359352
[TBL] [Abstract][Full Text] [Related]
18. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.
Goethaert K; Van Looveren M; Lammens C; Jansens H; Baraniak A; Gniadkowski M; Van Herck K; Jorens PG; Demey HE; Ieven M; Bossaert L; Goossens H
Clin Microbiol Infect; 2006 Jan; 12(1):56-62. PubMed ID: 16460547
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit.
Bassetti M; Righi E; Fasce R; Molinari MP; Rosso R; Di Biagio A; Mussap M; Pallavicini FB; Viscoli C
J Antimicrob Chemother; 2007 Aug; 60(2):433-5. PubMed ID: 17540673
[TBL] [Abstract][Full Text] [Related]
20. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults.
Jimenez-Cruz F; Jasovich A; Cajigas J; Jiang Q; Imbeault D; Woods GL; Gesser RM;
Urology; 2002 Jul; 60(1):16-22. PubMed ID: 12100914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
